About ImmPACT-Bio
ImmPACT-Bio is a company based in Ness Ziona (Israel) founded in 2017 was acquired by Lyell Immunopharma in October 2024. ImmPACT-Bio has raised $157.86 million across 3 funding rounds from investors including Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical. ImmPACT-Bio offers products and services including Bispecific CAR T Cells and TGF-β CAR.
- Headquarter Ness Ziona, Israel
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immpact Bio, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$157.86 M (USD)
in 3 rounds
-
Latest Funding Round
$8 M (USD), Grant
Feb 29, 2024
-
Investors
Lyell Immunopharma
& 13 more
-
Employee Count
Not available
-
Acquired by
Lyell Immunopharma
(Oct 24, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmPACT-Bio
ImmPACT-Bio offers a comprehensive portfolio of products and services, including Bispecific CAR T Cells and TGF-β CAR.
Bispecific CAR T cells are employed to prevent antigen escape in cancer and autoimmune diseases
TGF-β CAR is utilized to rewire T cell responses against immunosuppressive microenvironments in cancer
People of ImmPACT-Bio
Unlock access to complete
Unlock access to complete
Funding Insights of ImmPACT-Bio
ImmPACT-Bio has successfully raised a total of $157.86M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $8 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImmPACT-Bio
ImmPACT-Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked |
Investor details for ImmPACT-Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImmPACT-Bio
Investment portfolio details for ImmPACT-Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmPACT-Bio
Detailed financials for ImmPACT-Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immpact-Bio Comparisons
Peer comparison for ImmPACT-Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmPACT-Bio
Detailed competitors of ImmPACT-Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immpact-Bio
Complete news archive for ImmPACT-Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmPACT-Bio
ImmPACT-Bio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
ImmPACT-Bio is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Merav Beiman is the current CEO of ImmPACT-Bio.
ImmPACT-Bio is a funded company, having raised a total of $157.86M across 3 funding rounds to date.
ImmPACT-Bio was founded in 2017 and is based in Ness Ziona, Israel. Operations in the biotechnology sector are centered on the advancement of biological products and therapies. Research efforts are led by CEO Merav Beiman, with a focus on innovative medical solutions. Activities are conducted primarily in Israel, addressing needs in biopharmaceutical applications across various therapeutic areas. Limited details on specific services are available.
ImmPACT-Bio offers Bispecific CAR T Cells and TGF-β CAR.
ImmPACT-Bio has 14 investors. Key investors include Lyell Immunopharma, Orbimed, Bukwang Pharmaceutical, venBio, and Foresite Capital.